The global Non-Alcoholic Steatohepatitis (NASH) Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The USA market for Global Non-Alcoholic Steatohepatitis (NASH) Drugs market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global Non-Alcoholic Steatohepatitis (NASH) Drugs market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Non-Alcoholic Steatohepatitis (NASH) Drugs market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
This report aims to provide a comprehensive presentation of the global market for Non-Alcoholic Steatohepatitis (NASH) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Alcoholic Steatohepatitis (NASH) Drugs. This report contains market size and forecasts of Non-Alcoholic Steatohepatitis (NASH) Drugs in global, including the following market information:
- Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2022 (%)
This market is boosted by the growing prevalence of diabetes and obesity, and high investments for research and development, which leads to rising demand for NASH and others nonalcoholic fatty liver diseases (NAFLD) therapies in the market. As per the regional analysis, the well-established healthcare infrastructure with the high adoption rate of new technologies and increasing research activities, makes North America dominate this market.
We surveyed the Non-Alcoholic Steatohepatitis (NASH) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Percentages, by Type, 2022 (%)
- Vitamin E & Pioglitazone
- Obeticholic Acid (OCA)
- Elafibranor
- Selonsertib & Cenicriviroc
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Percentages, by Application, 2022 (%)
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Non-Alcoholic Steatohepatitis (NASH) Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Non-Alcoholic Steatohepatitis (NASH) Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- AstraZeneca
- Conatus Pharmaceuticals
- Enzo Biochem
- Galmed Pharmaceuticals
- Genfit
- Gilead
- Horizon Pharma
- Immuron
- Intercept Pharmaceuticals
- Novo Nordisk
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Alcoholic Steatohepatitis (NASH) Drugs, market overview.
Chapter 2: Global Non-Alcoholic Steatohepatitis (NASH) Drugs market size in revenue.
Chapter 3: Detailed analysis of Non-Alcoholic Steatohepatitis (NASH) Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Alcoholic Steatohepatitis (NASH) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
